1.

論文

論文
篁, 俊成
出版情報: 金沢大学十全医学会雑誌.  115  pp.99-103,  2006-06-01.  金沢大学十全医学会
URL: http://hdl.handle.net/2297/9767
2.

論文

論文
Xu, Liang ; Nagata, Naoto ; Ota, Tsuguhito ; 長田, 直人 ; 太田, 嗣人
出版情報: Adipocyte.  7  pp.218-225,  2018-08-09.  Taylor & Francis
URL: http://hdl.handle.net/2297/00051317
概要: 金沢大学医薬保健研究域医学系<br />Obesity is a low-grade sustained inflammatory state that causes oxidative stress in different metabolic tissues, which leads to insulin resistance and nonalcoholic fatty liver disease (NAFLD). Particularly, obesity-induced metabolic endotoxemia plays an important role in the pathogenesis of insulin resistance and inflammation. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator of antioxidant signaling that serves as a primary cellular defense against the cytotoxic effects of oxidative stress. Pharmacological stimulation of Nrf2 mitigates obesity and insulin resistance in mice; however, Nrf2 activators are not clinically available due to biosafety concerns. A recent study demonstrated that glucoraphanin, a precursor of the Nrf2 activator sulforaphane, ameliorates obesity by enhancing energy expenditure and browning of white adipose tissue, and attenuates obesity-related inflammation and insulin resistance by polarizing M2 macrophages and reducing metabolic endotoxemia. Thus, this review focuses on the efficiency and safety of glucoraphanin in alleviating obesity, insulin resistance, and NAFLD.<br />Embargo Period 12 months 続きを見る